Credit: Arcutis. Zoryve cream contains roflumilast, a phosphodiesterase type 4 inhibitor. Zoryve (roflumilast) cream 0.15% is now available for the topical treatment of mild to moderate atopic ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. More than a quarter of patients achieved a clear or ...
Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. AD affected more than 35% body surface area of study ...
Still itching after topical steroids? Here's why your atopic dermatitis symptoms may still be flaring and what you can do about it.
ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well tolerated Once-daily, steroid-free cream can be used anywhere ...
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced efficacy and safety results from a pooled analysis of two randomized, double-blind, vehicle-controlled Phase 3 studies – ...
Perioral dermatitis is a common skin condition. I share how I finally managed my flare-ups with the help of dermatologists ...
Investigational ZORYVE cream 0.05% was formulated for the delicate skin of infants and young children with mild to moderate atopic dermatitis Topline results anticipated in Q1 2026 The U.S. FDA ...
Emirates Drug Establishment Approves Tapinarof Cream 1%, A New Treatment For Plaque Psoriasis In Adults And Atopic Dermatitis ...
Credit: Arcutis. The approval was supported by data from the phase 3 INTEGUMENT-1 and INTEGUMENT-2 trials. The Food and Drug Administration (FDA) has approved Zoryve ® (roflumilast) cream 0.15% for ...
Atopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children in the U.S. WESTLAKE VILLAGE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. ...